TAK-715 Catalog No.:M10952-2 and caspase-9 and poly (ADP)

and caspase-9 and poly (ADP) ribosome polymerase

The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

000-fold selectivity for PHD2 over other 2OG-dependent dioxygenases

CAS Number: 1245319-54-3

22)23)25-14(9)11

TAK-715 Catalog No.:M10952-2 and caspase-9 and poly (ADP)TAK 715 is a potent p38 MAPK inhibitor. which displays potent inhibitory activity (inhibition of p38alpha, IC50 = 7. 1 nM; LPS stimulated release of TNF alpha from THP 1, IC50 = 48 nM; LPS induced TNF alpha production in mice, 87. 6% inhibition at 10 mg kg, po) and no inhibitory activity for major CYPs, including CYP3A4. TAK 715 was selected as a clinical candidate and is now under clinical investigation for the treatment of RA. Product information